Northland Capmk Issues Positive Forecast for TLSI Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Stock analysts at Northland Capmk boosted their FY2026 EPS estimates for shares of TriSalus Life Sciences in a research report issued to clients and investors on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings of ($0.60) per share for the year, up from their previous forecast of ($0.75). Northland Capmk has a “Strong-Buy” rating on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

Several other research analysts also recently commented on the company. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Roth Mkm assumed coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 price target on the stock. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective for the company. Oppenheimer started coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price on the stock. Finally, Canaccord Genuity Group reduced their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Stock Performance

TriSalus Life Sciences stock opened at $4.25 on Thursday. The company has a market capitalization of $129.58 million, a PE ratio of -1.71 and a beta of 0.49. The company has a 50 day moving average price of $4.22 and a 200-day moving average price of $5.47. TriSalus Life Sciences has a fifty-two week low of $3.61 and a fifty-two week high of $10.42.

Insider Activity at TriSalus Life Sciences

In other news, CEO Mary T. Szela acquired 7,520 shares of TriSalus Life Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. The trade was a 2.03 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have purchased a total of 19,560 shares of company stock valued at $95,190 over the last quarter. 32.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Several institutional investors have recently bought and sold shares of the company. Highbridge Capital Management LLC purchased a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at $1,184,000. Wolverine Asset Management LLC acquired a new position in TriSalus Life Sciences during the 2nd quarter valued at about $240,000. Duquesne Family Office LLC raised its stake in TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the last quarter. Geode Capital Management LLC raised its stake in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in TriSalus Life Sciences in the third quarter worth about $92,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.